Abbott GmbH Max-Planck-Ring 2 65205 Wiesbaden, Germany

Single Registration Number (SRN): N/A



Urgent Field Safety Notices Urgent Product Correction

Immediate Action Required

Date Issued

June 9, 2022

Product

Product Description	List Number	Lot Number	US/ EU UDI
ARCHITECT Hemoglobin A1c (A1c)	4P52-20	59588UQ04	(01)00380740102746(17)220707(10)59588UQ04
		59868UQ05	(01)00380740102746(17)220811(10)59868UQ05
		59900UQ06	(01)00380740102746(17)220909(10)59900UQ06
		60138UQ07	(01)00380740102746(17)221011(10)60138UQ07
		60237UQ08	(01)00380740102746(17)221104(10)60237UQ08
		60535UQ08	(01)00380740102746(17)221111(10)60535UQ08
		60698UQ09	(01)00380740102746(17)221229(10)60698UQ09
		60880UQ10	(01)00380740102746(17)230126(10)60880UQ10
		61066UQ11	(01)00380740102746(17)230223(10)61066UQ11
		61246UQ01	(01)00380740102746(17)230404(10)61246UQ01
		61250UQ01	(01)00380740102746(17)230410(10)61250UQ01

Explanation

This letter is to inform you of a potential for falsely elevated Hemoglobin %A1c and Hemoglobin A1c patient results to be generated using the ARCHITECT Hemoglobin A1c assay when analyzing whole blood or hemolysate samples with poor sample integrity, due to microclots and particulate matter, associated with low Total Hemoglobin values. To address this issue, a revision to the Total Hemoglobin low linearity value for the ARCHITECT Hemoglobin A1c whole blood and hemolysate applications has been implemented.

The SPECIMEN COLLECTION AND HANDLING and Assay Procedure, Whole Blood Preparation and Hemolysate Preparation sections of the ARCHITECT Hemoglobin A1c assay insert provide appropriate sample preparation instructions to ensure an optimal sample is presented for analysis.

The following whole blood and hemolysate Total Hemoglobin assay parameter changes have been implemented to reduce the potential for falsely elevated Hemoglobin %A1c and Hemoglobin A1c results to occur:

- Low-Linearity value for the Total Hemoglobin Whole Blood assay file (THbWB) was increased from 12.7302 μmol/L to 53.8278 μmol/L.
- Low-Linearity value for the Total Hemoglobin Hemolysate assay file (THbH) was increased from 295.5947 μmol/L to 1250 μmol/L.

There is no change to the measuring interval of the calculated assays.

Impact on Patient Results

There is a potential for falsely elevated Hemoglobin %A1c and Hemoglobin A1c patient results.

Necessary Actions to be Taken by Customer

 Immediately install the updated assay file versions listed below (as applicable for your laboratory), and then manually configure the Low-Linearity value. The assay files can be obtained from www.corelaboratory.abbott

Whole Blood Application

Hemolysate Application

Assay File	Assay No.	Version
THbWB	1105	5
%A1cWB	3075	5
A1cWB	3074	5
HbA1cWB	1106	5

Assay File	Assay No.	Version
THbH	1107	6
%A1cH	3077	6
A1cH	3076	6
HbA1cH	1108	6

2. For the whole blood application, manually configure the **THbWB** Low-Linearity to **53.8278.**

For the hemolysate application, manually configure the **THbH** Low-Linearity to **1250**.

For detailed information on editing assay parameters, refer to Changing assay configuration settings, Change a linearity range in the ARCHITECT System Operations Manual, Section 2.

- Please review this letter with your Medical Director or Laboratory Management and follow your laboratory protocol regarding the need for reviewing previously reported patient results.
- 4. Complete and return the Customer Reply Form.
- 5. Please retain this letter for your laboratory records.
- 6. If you have forwarded the product listed above to other laboratories, please inform them of this Product Correction and provide to them a copy of this letter.

Contact Information

We sincerely regret any inconvenience this may have caused your laboratory. If you or any of the health care providers you serve have questions regarding this information, U.S. Customers please contact Customer Service at 1-877-4ABBOTT (available 24 hours a day, 7 days a week). Customers outside the U.S., please contact your local area Customer Service.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online (http://www.fda.gov/MedWatch/report.htm), by mail (http://www.fda.gov/MedWatch/getforms.htm), by phone (1-800-332-1088), or by fax (1-

(http://www.fda.gov/MedWatch/getforms.htm), by phone (1-800-332-1088), or by fax (1-800-FDA-0178).

If you have experienced any patient or user injury associated with this Field Action, please immediately report the event to your local area Customer Service.